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Abstract 
Background: Heart failure (HF), especially with preserved ejection fraction (HFpEF) is common in older patients with 
type 2 diabetes (T2DM), but often not recognized. Early HF detection in older T2DM patients may be worthwhile 
because treatment may be initiated in an early stage, with clear beneficial treatment in those with reduced ejection 
fraction (HFrEF), but without clear prognostic beneficial treatment in those with HFpEF. Because both types of HF may 
be uncovered in older T2DM, screening may improve health outcomes at acceptable costs. We assessed the cost‑
effectiveness of five screening strategies in patients with T2DM aged 60 years or over.
Methods: We built a Markov model with a lifetime horizon based on the prognostic results from our screening study 
of 581 patients with T2DM, extended with evidence from literature. Cost‑effectiveness was calculated from a Dutch 
healthcare perspective as additional costs (Euros) per additional quality‑adjusted life‑year (QALY) gained. We per‑
formed probabilistic sensitivity analysis to assess robustness of these outcomes. Scenario analyses were performed to 
assess the influence of the availability of effective treatment of heart failure with preserved ejection fraction.
Results: For willingness to pay values in the range of €6050/QALY–€31,000/QALY for men and €6300/QALY–€42,000/
QALY for women, screening‑based checking the electronic medical record for patient characteristics and medical 
history plus the assessment of symptoms had the highest probability of being cost‑effective. For higher willingness‑
to‑pay values, direct echocardiography was the preferred screening strategy. Cost‑effectiveness of all screening strate‑
gies improved with the increase in effectiveness of treatment for HFpEF.
Conclusions: Screening for HF in older community‑dwelling patients with T2DM is cost‑effective at the commonly 
used willingness‑to‑pay threshold of €20.000/QALY by checking the electronic medical record for patient charac‑
teristics and medical history plus the assessment of symptoms. The simplicity of such a strategy makes it feasible for 
implementation in existing primary care diabetes management programs.
Keywords: Heart failure, Type 2 diabetes, Screening, Quality of life, Cost‑effectiveness
© 2016 van Giessen et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Type 2 diabetes mellitus (T2DM) is known to increase 
the risk for cardiovascular disease, including coronary 
artery disease and ‘diabetic cardiomyopathy’ [1, 2]. 
Heart disease is hence a major cause of death among 
T2DM patients [1, 3–5]. In a screening study, we recently 
showed that among T2DM patients aged 60 years or over, 
27.7  % had unrecognized heart failure (HF); 22.9  % HF 
with preserved ejection fraction (HFpEF) and 4.8  % HF 
with reduced ejection fraction (HFrEF) [5]. For HFrEF 
prognostically beneficial treatment is available, while this 
is lacking for HFpEF [6]. New drugs for HFpEF, however, 
are currently under investigation.
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Early HF detection in older T2DM patients may be 
worthwhile because treatment may be initiated in an 
early stage. Moreover, adequate diagnosis of HF may 
prevent misclassification of symptoms, such as short-
ness of breath as a respiratory disease [13]. However, 
in the light of limited healthcare resources, balancing 
healthcare interventions and costs has become increas-
ingly important. Screening older T2DM patients for HF 
will induce costs for testing, as well as downstream costs 
for additional check-ups and treatment. On the other 
hand, early HF detection may increase health effects 
through early treatment initiation. As treatment may 
prevent HF progression, this might save costs on the 
long-term. If a screening strategy shows it can achieve 
health effects at acceptable costs, large-scale implemen-
tation within existing primary care diabetes manage-
ment programs may be advocated. Currently, there is no 
such HF screening program among older community-
dwelling T2DM patients diabetes in the Netherlands. 
We therefore assessed the long-term health effect and 
costs of five screening strategies to detect HF in T2DM 
patients aged 60 years or over in the Dutch primary care 
setting.
Methods
The UHFO‑DM2 study
We conducted the ‘UHFO-DM2’ screening study from 
February 2009 to March 2010, within which participants 
were followed for 1 year [7]. All T2DM patients enlisted 
in primary care practices in the South-West of the Neth-
erlands were eligible to participate. In total 581 patients 
who did not already have a cardiologist-confirmed diag-
nosis of HF and gave written informed consent were 
included in the study. The study complied with the dec-
laration of Helsinki and was approved by the institu-
tional review and ethics boards of the University Medical 
Center Utrecht and the Admiraal de Ruyter Hospital in 
Goes, the Netherlands. The study is registered in the reg-
ister of the Central Committee on Research Involving 
Human Subjects (NL22717.041.08).
All 581 participants underwent a 1-day standardized 
diagnostic assessment including history taking, physical 
examination, electrocardiography (ECG), blood tests, and 
echocardiography. Presence of HF (HFpEF or HFrEF) was 
determined by an expert-panel consisting of two cardiolo-
gists and an experienced general practitioner (GP) who 
followed the criteria for HF of the recent European Society 
of Cardiology guidelines [2, 7]. Preference-based utilities 
were measured with the EuroQol-5D (EQ5D) instrument 
during the baseline visit [8]. After 3 and 12  months the 
participants filled out the same questionnaires, plus an 
additional questionnaire on medication use.
Overview of the screening strategies
We assessed the cost-effectiveness of five screening 
strategies:
1. EMR/symptoms; a strategy based on information 
available from the Electronic Medical Record (EMR) 
of general practitioners, i.e., age, gender, history of 
ischaemic heart disease, asthma or COPD, hyper-
tension, peripheral arterial disease, transient ischae-
mic attack or stroke, combined with the assessment 
of presence of the following symptoms; dyspnea, 
fatigue, ankle oedema, nocturia, or palpitations.
2. EMR/symptoms/PhysicalExam; strategy 1 plus fea-
tures from the physical examination (PE): pulmo-
nary crepitations, jugular venous distension, ankle 
oedema, or a laterally displaced apex beat.
3. EMR/symptoms/PhysicalExam/NTproBNP; strat-
egy 2 plus measurement of natriuretic peptide 
(NTproBNP) applying the exclusionary cut-point of 
15 pmol/L (≈125 pg/ml).
4. EMR/symptoms/PhysicalExam/NTproBNP/ECG; 
strategy 3 plus ECG.
5. Echocardiography; everybody is directly referred for 
echocardiography.
Strategy 1 to 4 are based on recently developed diag-
nostic screening models to estimate the risk of HF in 
T2DM patients [9]. A risk of <20 % was used for ruling 
out HF, and to estimate the sensitivity and specificity of 
the different strategies [10]. In our screening models, 
patients were referred for echocardiography if the HF 
risk was ≥20  %. All the initial, once-in-a-life screening 
strategies were followed by annual assessment of EMR/
symptoms.
Model structure
To assess long-term consequences in terms of costs and 
health effects of the five screening strategies compared 
to no screening (usual care), a Markov decision analytic 
cohort model of HF progression was developed (Fig. 1). 
Markov models assume that a patient is always in one of 
the predefined health states. In this, here representing 
HF progression, and use transition probabilities to allow 
patients to transition between health states over time. 
Each health state is assigned a (time-dependent) utility 
and cost. The long-term expected health effects and costs 
of each (screening) strategy can be calculated by multi-
plying the total time spent in each state by the utilities 
and costs corresponding to these states, respectively. We 
refer to the literature for further information. [11–13].
The model was designed to simulate hypothetical 
cohorts of men and women with T2DM initially screened 
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for HF at age 60. The model employed 3-months’ time 
cycles, corresponding to the regular interval of diabe-
tes consultations and a lifetime horizon, i.e., the simula-
tion stopped when all 581 patients in the hypothetical 
cohort had died. In the model, all individuals started in 
the diabetes without HF health state, or one of the four 
HF states based on the four New York Heart Association 
(NYHA) classes, subdivided in the categories ‘detected’ 
or ‘undetected’ [14]. In all screening, strategies individu-
als suspected of HF underwent echocardiography as the 
cornerstone investigation, which was assumed to be the 
reference standard with a sensitivity and specificity of 1.0.
Individuals without HF at the time of the initial screen-
ing could develop HF in subsequent years, which would 
transfer them to the health state NYHA II undetected. 
They could then be detected by the subsequent annual 
screening similar to the individuals with HF who were 
missed with the initial screening. Finally, all individuals 
could die from causes unrelated to HF, while HF patients 
could also die because of HF.
Input parameters
The baseline distribution of individuals over the differ-
ent health states was based on the UHFO-DM2 screening 
study with a screen-detected prevalence of HF of 27.7 % 
(22.9 % for HFpEF and 4.8 % for HFrEF) and the sensitiv-
ity and specificity of the screening strategy (Table 1) [5]. 
The risk of death from causes other than HF was based on 
age- and gender-specific Dutch life tables (Table 2), [15] 
whereas the risk of death from HF was estimated accord-
ing to the Seattle Heart Failure (SHF) model [5, 16]. The 
survival estimates of the SHF model were calculated 
using the mean predictor values from the UHFO-DM2 
cohort, stratified by gender and age categories (60–70, 
70–80 and 80+ years). The SHF model parameters daily 
defined dose for diuretic use, percentage lymphocytes, and 
uric acid were not obtained in the UHFO-DM2 cohort 
and therefore derived from the ELITE2 cohort, [3, 17] 
which was used for the validation of the SHF cohort [5, 
16]. The SHF model was developed in cases with HFrEF, 
whereas in the UHFO-DM2 cohort the majority of newly 
detected cases of HF had HFpEF (82.6 %) [5, 16]. In the 
main analysis, we therefore conservatively assumed there 
is no medication effect for patients with HFpEF [17–19].
Medication prescription of patients with undetected 
HF was based on the observed proportion of individu-
als in the UHFO-DM2 cohort using specific medication 
prior to their HF diagnosis. For detected HF the observed 
proportion of medication use 1 year after diagnosis in the 
UHFO-DM2 cohort was used (Table 2). With modeling, 
compliance to prescribed medication was assumed as no 
evidence for this patient group was available. The prob-
abilities of healthy individuals to develop HF were based 
on age- and gender- stratified HF incidence in the Neth-
erlands, taking into account the presence of diabetes [20, 
21]. Transition probabilities between different NYHA-
states were derived from 1-month transition probabilities 
of 65-years old HF patients who are on medical therapy 
Fig. 1 Schematic representation of the model structure. NYHA New York Heart Association, HF heart failure. Within each NYHA state patients can 
either have detected or undetected heart failure. Following the screening strategy patients can be diagnosed with heart failure and transition from 
the undetected to the detected state may take place. Patients can transition from NYHA IV to NYHA I because of the (small) probability of transition‑
ing to a better NYHA state in 1 month [22]. From the diabetes without HF and any of the NYHA states individuals can die from causes other than HF 
and transition to ‘Death other’
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[22]. With increasing age, the probability to regress to a 
worse state (higher NYHA-class) was increased similar to 
the increasing mortality risk according to the SHF model 
in the corresponding NYHA classes, taking into account 
whether the patient had detected or undetected HF [16]. 
The probability to regress to a better state was calculated 
accordingly.
Health outcomes
Health effects were determined by calculating expected 
life-years and quality-adjusted life-years (QALYs). Utili-
ties for each of the eight HF states and the state of diabe-
tes without HF were based on the EQ5D-scores obtained 
in the UHFO-DM2 study (Table 2). The utilities for unde-
tected HF were based on scores obtained before diagno-
sis, whereas utilities for diabetes without HF and detected 
HF states were based on EQ5D-scores obtained 1  year 
after diagnosis.
Costs
Our analysis was conducted from a healthcare perspec-
tive, incorporating costs directly related to screening and 
diagnosis, and HF-related costs for detected and unde-
tected HF patients within different NYHA-classes. Costs 
for screening and diagnosis included costs for inves-
tigations and consultation and, in case of a calculated 
risk of HF > 20 %, a cardiologist consultation including 
echocardiography. If HF was diagnosed, costs of a car-
diac ECG stress test were added. In the Netherlands, 
it is common practice for cardiologists to perform this 
test as a first step in the assessment if angina pectoris 
or myocardial ischaemia is involved [23]. All costs were 
based on tariffs set by the Dutch Healthcare Authority 
(1 January 2011) according to Dutch guidelines (Table 1) 
[24–26].
Long-term HF-related costs were split up into costs 
for all HF patients (hospitalization and nursing care) and 
costs for patients with detected HF (extra GP consulta-
tion and medication use), stratified by gender and age. 
All T2DM patients have regular GP consultations and 
receive anti-diabetes medication and the vast majority 
receives blood pressure lowering drugs and statins. We 
therefore solely used the increase in costs related to the 
detection of HF. Costs for all HF patients were addition-
ally weighted over NYHA classes using hazard ratios for 
hospitalization per NYHA class, which were adjusted for 
detected and undetected HF using the ratio of their mor-
tality risks based on the SHF model [16, 22].
Table 1 Sensitivity, specificity, and costs of heart failure screening strategies in patients with type 2 diabetes of 60 years 
or older
For each screening strategy NYHA-specific sensitivities were calculated and for each of these sensitivities a beta-distribution was specified with the true positives and 
total positives as parameters. Similarly, beta distributions were assigned to the specificities of each of the screening strategies. Gamma distributions with parameters 
using a variance equal to the mean were used for the costs
EMR Electronic Medical Record, GP general physician
a In general, more extensive screening strategies yielded higher sensitivity and specificity at higher costs, except for NYHA 2 when adding ECG and for NYHA 3 when 
adding NTproBNP and/or ECG
b Strategy costs in case of no screening are kept fixed at €0 in the sensitivity analyses
c There are no GP costs here as everyone is, after their regular diabetes checkup, directly sent for echocardiography
Parameters 0
No screening
1
EMR symp‑
toms
2
EMR symptoms
Physical exam
3
EMR symptoms
Physical exam
NTproBNP
4
EMR symptoms
Physical exam
NTproBNP ECG
5
Echo
cardio‑
graphy
Distribution Source
Sensitivitya
 NYHA 1 0.000 0.250 0.250 0.250 0.500 1.000 Beta Cohort [5]
 NYHA 2 0.000 0.853 0.853 0.879 0.862 1.000 Beta Cohort [5]
 NYHA 3 0.000 0.923 0.949 0.897 0.897 1.000 Beta Cohort [5]
 NYHA 4 0.000 1.000 1.000 1.000 1.000 1.000 Beta Cohort [5]
Specificity 1.000 0.610 0.617 0.652 0.676 1.000 Beta Cohort [5]
Screening
 GP €0.00b €6.39 €15.17 €36.67 €61.77 €0.00c Gamma Dutch tariff 
[24–26]
 Echocardiog‑
raphy
€169.38 €169.38 €169.38 €169.38 €169.38 €169.38 Gamma Dutch tariff 
[24–26]
 ECG stress test €94.75 €94.75 €94.75 €94.75 €94.75 €94.75 Gamma Dutch tariff 
[24–26]
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Analyses
Life-years, QALYs, and costs per person were calculated 
over a lifetime horizon, with costs and health effects dis-
counted at 4 and 1.5 % per year, respectively, according to 
Dutch guidelines [27]. To assess robustness of the results 
given the uncertainty in the evidence (Table  2), proba-
bilistic sensitivity analyses were performed using Monte 
Carlo simulation based on 10,000 samples. The incre-
mental cost-effectiveness ratios (ICERs) were calculated 
by first ranking all strategies in order of improving health 
outcomes and calculating the additional costs of obtain-
ing these health outcomes [12]. Strategies offering no 
additional health benefits, or additional health benefits at 
too high costs compared to other strategies were consid-
ered ‘dominated’, i.e., less favourable and not cost-effec-
tive, which was visualized in a cost-effectiveness frontier. 
Model development and analyses were done with Micro-
soft Excel 2010.
Scenario analyses for HFpEF medication
We distinguished between screening for HFrEF and 
HFpEF, because the prevalence is much higher for HFpEF, 
while convincing evidence-based therapy is only available 
for HFrEF. Treatment of HFpEF is focused on reduction 
of symptoms of fluid overload, adequate blood pressure 
control and management of comorbid conditions [2]. 
Diuretics are the only option for symptom relief, but their 
prognostic effects have never been adequately evaluated. 
Other drugs, including beta-blockers, angiotensin-con-
verting-enzyme inhibitors, angiotensin II receptor block-
ers and mineralo-corticoid inhibitors have been tested 
in randomized-controlled trials in patients with HFpEF, 
Table 2 Input parameters for the Markov model men and women with type 2 diabetes of 60 years or older
a Annual HF costs were mostly higher for undetected than for detected HF patients. Annual HF costs for detected female HF patients in NYHA class I-III were 
somewhat higher than for undetected female HF patients in corresponding NYHA classes because of higher use of primary care and medication
b Utilities were assumed to be the same in men and women. Utilities were higher for detected than for undetected HF patients except for NYHA class IV, where 
utilities were 0.665 and 0.683, respectively
Parameters Men Women Distribution Data source
Detected Undetected Detected Undetected
Incidence
 (100,000 person‑years) 658 666 Fixed Population estimates 23;24
HF Prevalence
 NYHA I 0.007 0.000 Dirichlet Cohort study [5]
 NYHA II 0.148 0.142 Dirichlet Cohort study [5]
 NYHA III 0.047 0.031 Dirichlet Cohort study [5]
 NYHA IV 0.000 0.000 Dirichlet Cohort study [5]
Mortality (year) 0.010 0.007 Fixed Population estimates [20]
HF Mortality (year)
 NYHA I 0.042 0.043 0.035 0.036 Fixed Cohort estimate [5]
 NYHA II 0.066 0.067 0.056 0.057 Fixed Cohort estimate [5]
 NYHA III 0.103 0.105 0.087 0.089 Fixed Cohort estimate [5]
 NYHA IV 0.159 0.163 0.137 0.139 Fixed Cohort estimate [5]
Annual HF costsa
 NYHA I €1777 €1786 €1172 €1100 Gamma Cost study [38]
 NYHA II €2099 €2114 €1370 €1302 Gamma Cost study [38]
 NYHA III €3235 €3275 €2070 €2018 Gamma Cost study [38]
 NYHA IV €8752 €8912 €5470 €5490 Gamma Cost study [38]
Medication prescription
 ACE‑inhibitors 0.53 0.53 0.27 0.18 Cohort study [5]
 Beta‑blockers 0.57 0.50 0.50 0.50 Cohort study [5]
Utilitiesb
 Diabetes without diagnosed HF 0.868 Beta Cohort study [5]
 NYHA I 0.855 0.817 Beta Cohort study [5]
 NYHA II 0.790 0.739 Beta Cohort study [5]
 NYHA III 0.734 0.685 Beta Cohort study [5]
 NYHA IV 0.665 0.683 Beta Cohort study [5]
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mainly in addition to diuretics, with at the best a statis-
tically non-significant relative risk reduction in all-cause 
mortality of around 10 % [2].
Currently, medication for HFpEF has only shown at 
best a tendency to a mortality-reducing effect. [17, 28–
31] Therefore, scenario analyses were performed to assess 
the potential cost-effectiveness if evidence on effective 
medication for HFpEF becomes available in the future. 
We varied the effectiveness of medication for patients 
with HFpEF from 0 to 100 %, with increments of 10 %, of 
the effectiveness for HFrEF. Hence, 100 % implies equal 
effectiveness in HFpEF as in HFrEF. Incremental QALYs 
and costs of the screening strategies were evaluated for 
each of these HFpEF medication effectiveness scenarios. 
[17, 28–31] Scenario analyses were performed to assess 
the potential cost-effectiveness if mortality reducing 
effective medication for HFpEF becomes available in 
the future. We varied the effectiveness of medication for 
patients with HFpEF from 0 to 100 % effectiveness com-
pared to the effect in HFrEF, with increments of 10 %, i.e., 
100 % implies equal effectiveness in HFpEF as in HFrEF. 
The ICER of the screening strategies was evaluated for 
each of these scenarios of medication effectiveness in 
HFpEF.
Results
The average expected life-years and QALYs for 60-year 
old men and women with T2DM increased with HF 
screening, starting at the age of 60. For men, the expected 
life-years were 14.726 (12.345 QALYs) for usual care (no 
screening) and 14.742 (12.477 QALYs) if EMR/symptoms 
or strategy 2–4 were used. If echocardiography was per-
formed straightaway in all patients (strategy 5), expected 
life-years were 14.742 and QALYs 12.479. For women, 
expected life-years increased from 16.830 (14.047 
QALYs) with usual care to 16.851 (14.215 QALYs) if 
the EMR/symptoms strategy was implemented, and to 
16.852 (14.217 QALYs) with the Echocardiography strat-
egy. For usual care, expected lifetime costs for men and 
women were €6795 and €5024, respectively. These costs 
increased if screening strategies were performed, with 
the highest costs for the Echocardiography strategy; 
€7667 for men and €6152 for women (Table 3). The incre-
mental cost-effectiveness planes for the five screening 
strategies as compared to usual care (no screening) are 
presented in Fig. 2.
The cost-effectiveness acceptability curves (Fig.  3) 
showed that the EMR/symptoms strategy is the pre-
ferred strategy for a willingness to pay (WTP) ranging 
from €6050/QALY to €31,000/QALY for men and €6300/
QALY to €42,000/QALY for women. For lower WTP-
values, the usual care (no screening) strategy was opti-
mal, while for higher WTP-values the Echocardiography 
strategy is the preferred strategy. Comparing the different 
screening strategies and evaluating ICERs showed that 
QALYs could only be gained on top of the EMR/symp-
toms strategy by the Echocardiography strategy, and not 
by the other three strategies (Table 3 lower part, Fig. 4).
Scenario analyses for HFpEF medication
The ICERs of all strategies become more favourable 
with increasing medication effectiveness. For a WTP of 
€20,000/QALY EMR/symptoms is the preferred strategy. 
Increasing the relative HFpEF medication effectiveness 
Echocardiography is the preferred strategy in men if this 
relative medication effectiveness is 90 % or more. With a 
WTP of €80.000 Echocardiography is the preferred strat-
egy for any relative effectiveness (Table 4).
Discussion
Screening community-dwelling T2DM patients of 
60 years or over annually for HF in the Dutch primary 
care setting results in a small increase in life expec-
tancy and QALYs at relatively low costs. Checking the 
EMR for risk factors plus assessment of specific symp-
toms is the preferred initial, once-in-a-life strategy, 
with an ICER of €6115 for men and €6318 for women 
as compared to no screening. For a WTP of €20,000/
QALY, a commonly used threshold for patient care in 
Europe, this strategy would thus be cost-effective [26]. 
If patients with HFrEF would be treated optimally 
according to the guidelines, instead of e.g., the cur-
rent uptake of the most beneficial medication in heart 
failure, betablockers, which was 58  %, the cost-effec-
tiveness of screening T2DM patients will even be more 
favourable.
In the base-case analysis we assumed no beneficial 
prognostic effects of treatment for patients with HFpEF. 
We performed scenario analyses in which we evaluated 
the cost-effectiveness considering varying prognos-
tic beneficial treatment effects in this type of HF. These 
scenario analysis showed that if beneficial medication 
becomes available for HFpEF, screening strategies in 
older T2DM patients would have a more favourable 
ICER, reaching to €3709/QALY for men and €4502/
QALY for women, assuming a treatment effect for HFpEF 
that is 50  % of the current treatment effect of HFrEF 
(Table 4).
Strengths and limitations of the study
We assessed multiple screening strategies, all feasible 
to implement in everyday primary care practice. Our 
model was based on real-life medication prescriptions 
in screen-detected HF cases from a cohort study in 581 
T2DM patients aged 60 years or over [5]. We only applied 
a single cut-off point for considering HF to be present. 
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However, when evaluating screening strategies often a 
single cut-off is used and the 20 % cut-off we applied has 
been used in earlier studies [10].
Although we did account for higher health-care costs 
for individuals with undetected HF, we did not consider 
the costs of a possible acute life-threatening exacerba-
tion of HF necessitating hospital admission. Incorpo-
rating such a risk in our model would result in much 
higher costs for the non-screening strategy, and thus in 
an even more favorable cost-effectiveness of screening. 
Furthermore, end-of-life costs and health deteriora-
tion in patients dying from HF may be underestimated 
because in the model patients could die while being in 
any NYHA state, not considering rapid disease progres-
sion. For example, in our model 30  % of the patients 
would die from HF while being in NYHA class II, and 
any progression to higher NYHA states with its asso-
ciated health losses immediately prior to death is not 
taken into account. However, the majority of HF deaths 
(64  %) in our model occurred in patients with NYHA 
class 3 and 4, indicating that this underestimation is 
limited.
Another limitation of our study is that the SHF model 
was derived from cohorts with only HFrEF patients, 
while the majority of patients with HF in the UHFO-
DM2 cohort had HFpEF. Moreover, some of the predic-
tor values of the SHF model were not available in the 
UHFO-DM2 cohort. Therefore, the effectiveness of med-
ication incorporated in the SHF model may not translate 
perfectly to our cohort. This issue has been addressed 
by assuming that HFpEF patients do not benefit of any 
treatment. The additional scenario analyses to assess 
the impact of the availability of prognostically beneficial 
medication for HFpEF on ICER were added to further 
address this issue.
Implications for research and policy
Our results support screening for HF among T2DM 
patients of 60  years or over based on the information 
available from the EMR plus assessment of specific symp-
toms suggestive of HF, followed by echocardiography 
in those with a calculated risk of HF of more than 20 %. 
Even though only for the (small) proportion of patients 
with HFrEF mortality-reducing medication is available, 
Table 3 The incremental comparison of expected life years, QALYs, costs, and ICERs for five screening strategies for heart 
failure in patients with type 2 diabetes of 60 years or older
In the upper part of the table the absolute expected life-years, QALYs, and costs are given for each strategy. In the lower part, for each strategy these life-years, QALYs 
and costs are compared to the current optimal strategy
EMR Electronic Medical Record, ICER incremental cost-effectiveness ratio
a This is the strategy expected to be optimal for a WTP of €20,000 per QALY
Strategy 0
No screening
1
EMR symptoms
2
EMR symptoms
Physical Exam
3
EMR symptoms
Physical exam
NTproBNP
4
EMR symptoms
Physical exam
NTproBNP ECG
5
Echocardiography
Life expectancy (years)
 Men 14.726 14.742 14.742 14.742 14.742 14.742
 Women 16.830 16.851 16.851 16.851 16.851 16.852
QALY expectancy (years)
 Men 12.345 12.477 12.477 12.477 12.477 12.479
 Women 14.047 14.215 14.215 14.216 14.215 14.217
Expected costs pp (euros)
 Men €6795 €7605 €7611 €7625 €7642 €7667
 Women €5024 €6086 €6093 €6107 €6125 €6152
Strategy comparison NA 1 vs 0 2 vs 1 3 vs 1 4 vs 1 5 vs 1
Additional QALYs to comparator
 Men NA 0.132 0.000 0.000 0.000 0.002
 Women NA 0.168 0.000 0.000 0.000 0.002
Additional costs to comparator
 Men NA €810 NA NA NA €62
 Women NA €1063 NA NA NA €66
ICER
 Men NA €6115a Dominated Dominated Dominated €29,100
 Women NA €6318a Dominated Dominated Dominated €39,326
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Fig. 2 Incremental cost‑effectiveness planes for patients with type 2 diabetes of 60 years or older. a Men. b Women
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Fig. 3 Cost‑effectiveness acceptability curves for patients with type 2 diabetes of 60 years or older. a Men. b Women
Page 10 of 12van Giessen et al. Cardiovasc Diabetol  (2016) 15:48 
this screening strategy is cost-effective when using a 
WTP of €20,000/QALY. Comparing this HF screen-
ing to other screening programs, the cost-effectiveness 
would be better than for cervix screening for instance, 
which currently costs €20,000-€50,000/QALY [32]. Fur-
thermore, whenever (evidence for) mortality-reducing 
medication becomes available for HFpEF, of which many 
experts are convinced [19, 33], the incremental costs/
QALY of the screening strategies will decrease consider-
ably, as can be seen in the scenario analyses for effective-
ness of HFpEF medication (Table  4). The results of this 
cost-effectiveness analysis were based on the Dutch set-
ting and may not directly be transferred to other coun-
tries. Further research is needed to translate our model to 
settings in other countries.
Our observations are in line with a registration study, 
which concluded that despite advances in patient man-
agement there is further potential to improve both the 
detection and management of patients with diabetes and 
coronary artery disease [34]. Furthermore, relatively tight 
glucose control has some cardiovascular benefits. HbA1c 
below 7.0  % as the goal to maximize the cardiovascular 
benefits remains suspended [35]. In addition, a multidis-
ciplinary risk assessment and management program for 
patients with diabetes mellitus intervention was associ-
ated with lower incidences of individual and total car-
diovascular complications, as well as all-cause mortality 
over 3 years follow-up. This study shows risk assessment 
was an effective approach to reduce future cardiovascular 
complications in diabetes patients [36]. Also the ‘St Vin-
cent’s screening to prevent heart failure’ study showed 
that among patients with cardiovascular risk factors, 
natriuretic peptide-based screening and collaborative 
care reduced left ventricular dysfunction, HF and major 
adverse cardiac events, and has a high probability of 
being cost-effective [37].
Conclusions
Screening for heart failure by simply checking the elec-
tronic medical record for patient characteristics and 
medical history plus the assessment of symptoms in 
community-dwelling patients with type 2 diabetes of 
60  years and older is cost-effective at the commonly 
used willingness-to-pay threshold of €20.000/QALY. The 
Fig. 4 Cost‑effectiveness frontier patients with type 2 diabetes of 60 years or older. For each strategy life‑years, QALYs and costs are compared to 
the current optimal strategy (lower part Table 3). The results are visualized in this cost‑effectiveness frontier, which uses strategy 1 (EMR + symp‑
toms) as the reference point, i.e., the origin
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simplicity of such a strategy makes it feasible for imple-
mentation in existing primary care diabetes management 
programs. Cost-effectiveness may improve considerably 
with the availability of effective treatment for heart fail-
ure with preserved ejection fraction.
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